Compare companies
Put any US companies we track side by side — SEC-sourced financials, ratios, forensic scores, and our Quality Score. Add up to four. No market price, no paywall.
MELINTA THERAPEUTICS, INC. /NEW/
| Metric | MELINTA THERAPEUTICS, INC. /NEW/ Healthcare |
|---|---|
| Quality Score | 22 / 100 |
| Revenue (latest) | $15M |
| Net income (latest) | −$29M |
| Operating margin | −293.8% |
| Net margin | −198.3% |
| Return on equity | −15.5% |
| Return on assets | −6.7% |
| Return on capital (ROCE) | −14.2% |
| Debt / equity | 1.32× |
| Revenue growth (YoY) | −33.9% |
| Altman Z″ (distress) | -3.79 |
| Accruals / assets | 32.2% |
Latest reported figures from each company's own SEC filings (XBRL) plus our derived scores. Blank where a line item isn't cleanly tagged — never estimated. Descriptive factors, not advice. Open a company for its full multi-year history.